Philips Worldwide Regulatory and Safety Footprint: 26-Market Registry Teardown

A comprehensive database analysis detailing Philips' 7,909 distinct registrations across 26 global markets, integrated with clinical trial data and patent portfolios.

Why the Global Footprint Matters

Evaluating a company's regulatory compliance requires looking beyond a single country's database. This is particularly true for Royal Philips (Philips), which has faced significant regulatory scrutiny in recent years, including an FDA consent decree regarding its respiratory care division.

A database analysis reveals that Philips holds 7,909 distinct registrations across 26 international markets (compiled from 18,510 matched records). A key finding of this global teardown is that the European Union (EU) is actually Philips' largest registry location, holding 2,877 distinct registrations—more than double its United States total of 1,403 distinct registrations.

This concentration indicates that Philips' primary compliance overhead and regulatory assets are heavily weighted toward Europe under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). By analyzing this global distribution, medtech managers, hospital procurement teams, and risk analysts can better understand how Philips' portfolio shifts by region and modality. For example, while respiratory recalls have dominated public perception, the clinical data layer showing 22 company-titled clinical trials and 681 USPTO ultrasound patents demonstrates a massive, ongoing R&D investment in active diagnostics and imaging systems.

For a detailed analysis of Philips' US-specific operations, including premarket pathways and facility listings, see our Philips FDA Device Footprint Guide. For a targeted review of the CPAP safety action, refer to our Philips CPAP PE-PUR Foam Recall Regulatory Teardown.

Data Sources and Methodology

The quantitative findings in this report are based on a consolidated extract of international medical device registries, clinical trials, and federal procurement databases compiled in June 2026.

Data Layers Audited

Global Registration Matrix: A consolidated database containing competitor footprints across 28 market columns: Argentina, Australia, Brazil, Canada, Colombia, Ecuador, Egypt, the European Union, India, Indonesia, Japan, Jordan, Kazakhstan, Kenya, South Korea, Malaysia, Mexico, Moldova, Montenegro, Saudi Arabia, Serbia, Singapore, South Africa, Taiwan, Thailand, the United Kingdom, Ukraine, and the United States.
US Government Procurement Layer: USAspending federal contract databases mapping procurement awards to primary medtech suppliers.
Clinical Trial Registry Layer: ClinicalTrials.gov full registry extracting study sponsorship, patient enrollment, study status, and intervention parameters.
Patent and Literature Layers: USPTO patents and European biomedical literature databases matching active medical equipment and imaging IP assignments.

Analysis Boundaries and Decision Rules

Distinct Registrations: Defined as unique registration keys or marketing authorizations issued by national health authorities (e.g., EUDAMED in the EU, TGA in Australia, Health Canada).
Company Brand Mapping: Counts are restricted to Philips-branded entities (e.g., Philips Medical Systems, Philips Respironics, and related corporate entities). Legacy acquired entities are mapped to the parent group.
Limitations and Exclusions: Public registries vary significantly in data depth. For instance, the European Union EUDAMED data reflects active actor registration and certified device listings under MDR/IVDR, but does not represent a complete historical inventory of legacy MDD/IVDD devices. In contrast, APAC and LATAM registries (such as Taiwan and Brazil) provide highly granular, product-level rows. Absence of data in a specific registry column does not imply the absence of physical commercial sales, but rather indicates that the registry is either not yet fully digitized, uses a dealer-based notification framework, or represents a narrow regional subset.

Regional Registration Analysis

Philips' registration footprint is highly diversified across five major geographical regions. The following table provides a complete breakdown of its 7,909 distinct registrations across all 28 audited markets:

Region	Market / Country	Registry Authority	Distinct Registrations	Percentage of Global Portfolio
North America	United States	FDA	1,403	17.74%
	Canada	Health Canada	528	6.68%
Europe	European Union	EUDAMED	2,877	36.38%
	Serbia	ALIMS	139	1.76%
	Montenegro	CINMED	62	0.78%
	United Kingdom	MHRA	28	0.35%
	Ukraine	State Service (MOH)	7	0.09%
	Moldova	AMDM	0	0.00%
LATAM	Argentina	ANMAT	97	1.23%
	Brazil	ANVISA	177	2.24%
	Ecuador	ARCSA	60	0.76%
	Mexico	COFEPRIS	37	0.47%
	Colombia	INVIMA	37	0.47%
APAC	Australia	TGA	588	7.43%
	Taiwan	TFDA	488	6.17%
	Singapore	HSA	374	4.73%
	Indonesia	Kemenkes	311	3.93%
	Malaysia	MDA	202	2.55%
	India	CDSCO	100	1.26%
	Thailand	Thai FDA	47	0.59%
	South Korea	MFDS	37	0.47%
	Japan	PMDA	6	0.08%
MEA / Other	Saudi Arabia	SFDA	260	3.29%
	Kazakhstan	NDDA	41	0.52%
	Jordan	JFDA	1	0.01%
	Kenya	PPB	1	0.01%
	South Africa	SAHPRA	1	0.01%
	Egypt	EDA	0	0.00%
Total	28 Markets	—	7,909	100.00%

Country-by-Country Regulatory Deep Dive

European Union (2877 distinct registrations)

The European Union (EU) represents Philips' largest registry location, holding 2,877 distinct registrations. Regulated under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) through the EUDAMED database, managing this transitional compliance load is a major operational priority. As Philips updates its technical documentation and clinical evaluation reports (CERs) to meet the new EU regulations, the company must work closely with Notified Bodies to avoid certification gaps. The high concentration of EU registrations shows that Philips has focused heavily on maintaining market access in Europe, which serves as a key commercial region for its imaging and diagnostic lines. EUDAMED registration requires detailed actor registration, product numbering (UDI-DI), and public listing of safety summaries, creating a highly structured transparency layer for Philips' operations. Furthermore, the EU MDR has introduced stricter requirements for clinical data and post-market clinical follow-up (PMCF). Philips has established comprehensive PMCF plans, including clinical registries and post-market surveys, to satisfy Notified Bodies and ensure the long-term validity of its CE certificates. This compliance overhead represents a substantial annual investment in clinical resources and engineering data compilation. In addition, Philips must monitor Notified Body capacity constraints, which have delayed reviews across the industry. The company coordinates with reference notified bodies in Europe to prioritize submissions for its high-volume diagnostic and patient monitoring lines, ensuring continuous supply chains. To ensure compliance, Philips has consolidated its QMS structures under centralized EU units, matching its manufacturing sites in Eindhoven and Best with unified notified body audit protocols.

United States (1403 distinct registrations)

The United States represents a critical commercial market for Philips, holding 1,403 distinct registrations. Regulated under the FDA's Center for Devices and Radiological Health (CDRH), this footprint covers diagnostic imaging systems, patient monitoring hardware, and clinical consumables. Premarket notifications [510(k)] are the primary vehicle for Class II devices, while Class III systems require Premarket Approval (PMA) dossiers. Maintaining this footprint has involved significant regulatory challenges in recent years, including an FDA consent decree regarding Philips' Respironics division. This safety action has required Philips to implement comprehensive QMS remediation plans and coordinate closely with the FDA to manage recall distribution and patient monitoring updates. U.S. compliance also requires continuous monitoring of facility registrations and device listings. Philips' manufacturing plants (including diagnostic assembly facilities in the U.S. and Europe) must register annually and pay the associated user fees. Post-market compliance is governed by 21 CFR Part 803 (Medical Device Reporting) and Part 806 (Corrections and Removals), requiring robust tracking of field performance and rapid reporting of safety events to the FDA. Additionally, Philips' U.S. operations leverage the electronic submission template (eSTAR) to expedite premarket reviews, aligning digital engineering data with FDA's review framework to reduce approval timelines for its diagnostic imaging systems. This structured review helps Philips coordinate software updates under the FDA's Predetermined Change Control Plan (PCCP), particularly for its diagnostic imaging workstation software, ensuring continuous compliance during iterative software upgrades.

Australia (588 distinct registrations)

Australia's TGA regulates medical devices under the Therapeutic Goods Act 1989. With 588 distinct registrations, Australia represents a major APAC hub for Philips. Foreign manufacturers must appoint a local Sponsor who acts as the primary contact for the TGA and holds the marketing authorization. The TGA enforces a detailed technical review process, which is simplified for devices that already hold EU CE marking or US FDA clearance under regulatory reliance provisions. However, Sponsors must still submit comprehensive dossiers showing compliance with Australian essential principles, including electrical safety and biocompatibility standards. Philips' TGA footprint is managed through its Australian subsidiary, ensuring that all product updates, safety alerts, and recall notifications are communicated to the TGA in compliance with national timelines. The high registration volume demonstrates a strong commercial position in Australia's public and private hospital networks. Additionally, the TGA requires Sponsors to participate in regular audits of local distribution and warehousing controls. Philips maintains compliant storage facilities in Sydney and Melbourne, satisfying local regulations for medical device logistics and post-market tracking. To support local clinical users, Philips provides extensive technical support and training programs, helping biomedical engineers in Australian hospitals maintain system uptime in compliance with local quality guidelines.

Canada (528 distinct registrations)

Health Canada regulates medical devices under the Medical Devices Regulations, requiring manufacturers to secure a Medical Device License (MDL) for Class II, III, and IV systems. Philips holds 528 MDL approvals, representing its fourth-largest registry concentration. As a participant in the MDSAP program, Philips utilizes its MDSAP audit certificates to satisfy Health Canada's quality system requirements, allowing for streamlined renewals and license amendments. Canadian regulations also require strict post-market reporting, including mandatory problem reporting (MPR) and recall management. Philips' Canadian regulatory affairs team coordinates with Health Canada during MDL evaluations, ensuring that technical changes are documented and approved. The Canadian market also requires French-language labeling for products distributed in Quebec, requiring Philips to maintain bilingual packaging and safety instructions. To support this, Philips maintains French translations of all user manuals and software interfaces, ensuring that healthcare providers across Canada can operate its diagnostic systems in compliance with federal guidelines. Furthermore, Health Canada requires separate Medical Device Establishment Licenses (MDEL) for importers and distributors, necessitating close coordination with Philips' local trade partners.

Taiwan (488 distinct registrations)

Taiwan's TFDA regulates medical devices under the Medical Devices Act. Foreign manufacturers must register their products through an authorized local importer who acts as the marketing authorization holder. Philips' quality team must secure a Quality System Documentation (QSD) certificate for each plant supplying the Taiwanese market. Product registration in Taiwan requires the submission of a detailed technical dossier following the ASEAN CSDT template. The dossier must contain electrical safety testing certificates, clinical evaluations, and traditional Chinese labeling translations. The 488 registrations held by Philips in Taiwan reflect a substantial investment in the country's healthcare system, supported by local regulatory specialists who manage TFDA submissions. The TFDA's review process focuses on verifying the equivalency of foreign clinical data. Philips utilizes its global clinical trial results to support these filings, minimizing the need for local testing and accelerating entry for its high-end imaging systems. Additionally, TFDA requires regular updates to QSD filings, demanding close coordination between Philips' global engineering teams and local registrants to ensure continuous compliance.

Singapore (374 distinct registrations)

The Health Sciences Authority (HSA) of Singapore regulates medical devices, holding 374 distinct registrations for Philips. Philips utilizes the HSA's expedited evaluation routes, leveraging prior approvals from reference agencies to accelerate market access. Singapore's regulations require local representative representation and strict compliance with national quality standards. Securing HSA listing is a prerequisite for participating in public hospital tenders, making Singapore a key commercial hub for Philips' interventional cardiology and imaging business in Southeast Asia. Additionally, the HSA requires robust post-market vigilance, including tracking of field safety corrective actions. Philips' local quality team coordinates with hospital biomedical departments to execute updates in compliance with HSA guidelines. This office also coordinates submissions across the broader ASEAN region, acting as a regional regulatory hub to harmonize filings and maintain consistent product descriptions.

Indonesia (311 distinct registrations)

Indonesia's Ministry of Health (Kemenkes) regulates medical devices, holding 311 distinct registrations for Philips. Foreign manufacturers must work with a local licensed importer who acts as the marketing authorization holder. Registrations in Indonesia require detailed technical files and conformity certificates. Kemenkes has recently implemented updates to its classification rules, requiring active maintenance of registry files. Philips' local regulatory team manages these updates, ensuring that all imported systems comply with local guidelines. Indonesia's government has also prioritized local manufacturing through local-content (TKDN) requirements. Philips manages this compliance gate by establishing local distribution agreements and monitoring TKDN rules to ensure continued access to public procurement channels. Furthermore, Kemenkes requires compliance with national quality standards (CDAKB), which involves auditing local distributor warehouses for temperature control and documentation.

Saudi Arabia (260 distinct registrations)

The Saudi Food and Drug Authority (SFDA) regulates medical devices, holding 260 distinct registrations for Philips. Foreign manufacturers must secure a Medical Device Marketing Authorization (MDMA) for all products imported into the Kingdom. The SFDA requires detailed technical files and enforces strict labeling requirements, including Arabic-language safety instructions. Saudi Arabia also requires foreign manufacturers to appoint a local representative and comply with national quality system audits, managed through the SFDA's digital GHAD portal. This digital registration framework requires Philips to maintain updated compliance files, ensuring that all testing certificates, clinical studies, and quality audit reports are accessible to SFDA assessors to prevent border clearance holds. SFDA also enforces strict UDI tracking rules, requiring all systems to carry compliant barcodes linked to the national registry database.

Malaysia (202 distinct registrations)

Malaysia's MDA regulates medical devices, holding 202 distinct registrations for Philips. Foreign manufacturers must register all products through a local licensed establishment. Registrations require third-party evaluation by a CAB and submission of CSDT technical files. Post-market requirements include mandatory reporting of adverse events and recalls. Philips' local quality team monitors product performance, ensuring compliance with MDA timelines. The MDA also requires local distributors to maintain a Good Distribution Practice for Medical Devices (GDPMD) certification. Philips audits its local logistics partners to ensure they maintain valid certificates, preventing import bottlenecks. Additionally, Malaysia enforces risk-based reviews, meaning high-risk systems like cardiovascular catheters face detailed technical audits before approval.

Serbia (139 distinct registrations)

The ALIMS of Serbia regulates market access, holding 139 distinct registrations for Philips. Serbian regulations are aligned with European Union directives, simplifying the registration of CE-marked systems, though local representative representation and Serbian-language labeling are still required. This alignment helps streamline the technical review process, though Philips must still compile local dossiers and coordinate with Serbian notified bodies to secure marketing authorizations. Serbian rules also mandate local tracking of device installations, requiring Philips to submit periodic lists of active capital equipment to ALIMS.

India (100 distinct registrations)

India's CDSCO regulates medical devices under the Medical Devices Rules 2017. Philips holds 100 distinct registrations in India, managed through its local subsidiary. The transition to a comprehensive licensing framework has required Philips to secure import licenses for its entire product range, adapting to local clinical trial requirements and CDSCO quality audits. Post-market reporting in India requires notifying CDSCO of serious adverse events within 15 days, necessitating close coordination between Philips' customer support team and hospital engineering departments. CDSCO rules also require foreign manufacturing plants to undergo registration and audit, prompting Philips to maintain continuous compliance records for its global production facilities.

Brazil (177 distinct registrations)

Brazil's ANVISA regulates medical devices under a strict risk-based classification system, holding 177 distinct registrations for Philips. For foreign manufacturers, the primary hurdle is securing Brazilian Good Manufacturing Practices (BGMP) certification for Class III and Class IV devices. ANVISA conducts on-site QMS inspections of foreign facilities, though it increasingly accepts quality certificates from the MDSAP program. Product registration in Brazil requires the submission of a detailed technical dossier (Relatório Técnico) in Portuguese, containing electrical safety testing certificates under the INMETRO scheme, clinical evaluations, and instructions for use. Post-market vigilance is governed by RDC 67/2009, requiring Philips to report adverse events, malfunctions, and recalls directly to ANVISA. This requires close coordination with local importing representatives to execute corrective actions.

Argentina (97 distinct registrations)

Argentina's ANMAT regulates medical devices, holding 97 distinct registrations for Philips. Foreign manufacturers must work with a local direct subsidiary or authorized importing representative to manage ANMAT filings and import logistics. ANMAT requires detailed technical dossiers and enforces strict quality system compliance, including audits of local importing warehouses to verify temperature control and tracking. Philips' local regulatory team manages these audits successfully, maintaining active import corridors.

Montenegro (62 distinct registrations)

The Institute for Medicines and Medical Devices of Montenegro (CINMED) regulates market access, holding 62 distinct registrations for Philips. Montenegrin regulations are aligned with European standards, simplifying the registration of CE-marked systems, though local representative representation and Montenegrin-language labeling are still required.

Ecuador (60 distinct registrations)

Ecuador's ARCSA requires a sanitary registry (Registro Sanitario) for all medical devices, holding 60 distinct registrations for Philips. Submissions must document conformity with international standards and include Spanish-language labeling translations, managed through local distribution partners.

Thailand (47 distinct registrations)

The Thai Food and Drug Administration (FDA) regulates medical devices, holding 47 distinct registrations for Philips. Thailand's risk-based classification system is aligned with the ASEAN AMDD, requiring detailed technical dossiers and conformity certificates to secure approvals.

Kazakhstan (41 distinct registrations)

The National Center for Expertise of Medicines and Medical Devices (NDDA) regulates market access in Kazakhstan, holding 41 distinct registrations for Philips. Submissions must comply with Eurasian Economic Union (EAEU) standards, requiring local representative representation and technical reviews.

Mexico (37 distinct registrations)

Mexico's COFEPRIS regulates medical devices, holding 37 distinct registrations for Philips. Registration requires detailed technical dossiers and conformity certificates, with foreign manufacturers working with a local registrant to manage COFEPRIS reviews and import logistics.

Colombia (37 distinct registrations)

Colombia's INVIMA regulates medical devices, holding 37 distinct registrations for Philips. INVIMA requires a sanitary registry (Registro Sanitario) for Class IIa, IIb, and III systems, with Philips leveraging INVIMA's automatic approval pathways for lower-risk products.

South Korea (37 distinct registrations)

South Korea's Ministry of Food and Drug Safety (MFDS) regulates devices, holding 37 distinct registrations for Philips. Submissions require testing by local laboratories to verify safety and electromagnetic compatibility (EMC), complying with Korean national standards.

United Kingdom (28 distinct registrations)

Following Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates devices in the UK. Philips holds 28 distinct registrations under the UKCA marking requirements, managed by a UK Responsible Person (UKRP).

Ukraine (7 distinct registrations)

Ukraine's MOH regulates medical devices, holding 7 distinct registrations for Philips. Ukrainian regulations are aligned with European directives, requiring local Authorized Representative (AR) representation and Ukrainian-language labeling.

Japan (6 distinct registrations)

Japan's PMDA regulates medical devices, holding 6 distinct registrations for Philips. PMDA enforces a rigorous regulatory framework, requiring foreign manufacturers to work with a local Marketing Authorization Holder (MAH) to manage PMDA reviews.

Other Audited Markets (Jordan, Kenya, South Africa, Egypt)

In the remaining audited markets, Philips maintains minor active registrations or establishment listings. In Jordan (1 distinct registration), Kenya (1), South Africa (1), and Egypt (0), the registration footprint reflects local representative-focused licensing. These registries primarily license the importer, meaning Philips' actual commercial footprint is managed through licensed local partners who handle import clearances on a product-by-product basis. To maintain compliance in these markets, Philips' global regulatory affairs team conducts regular audits of local partners, verifying that quality agreements are updated and that local distributors comply with regional quality standards (such as Good Distribution Practices in the Middle East and Africa). These audits evaluate distributor training, complaint handling, and recall capabilities, ensuring that Philips' global safety processes are executed consistently across all markets, regardless of local registry depth.

Product Category and Modality Distribution

Philips operates across 12 major business categories, spanning medical imaging, patient monitoring, and clinical consumables. The table below outlines how its 7,909 distinct registrations are distributed by product type:

Business Category	Record Count	Distinct Registrations	Markets Active	Core Technologies / Modalities Included
Other / Accessories	12,515	5,722	26	Patient monitoring sensors, cables, replacement parts, consumables
Imaging — Ultrasound	1,704	449	16	Epiq and Affiniti ultrasound systems, transducer arrays
Imaging — X-ray / Angiography	859	365	10	Azurion angiography suites, Mobile C-arms, fluoroscopic software
Interventional / Advanced Therapies	560	361	14	Laser atherectomy catheters, specialized guidewires, mapping systems
Digital Health / Software / IT	539	357	17	IntelliSpace PACS, clinical software suites, cloud monitoring portals
Imaging — MRI	861	281	14	Ingenia and Elition MRI series, RF coils, reconstruction software
Imaging — CT	369	229	14	Incisive and Spectral CT series, CT software applications
Imaging — General / Other	573	187	7	Digital radiography rooms, general radiography detectors
Radiation Oncology (Varian/Other)	120	82	7	Pinnacle treatment planning software, oncology workflow systems
Laboratory Diagnostics (IVD)	355	53	6	Specialized cardiac assays, diagnostic reagent kits
Hearing / Audiology	28	24	3	Infant hearing screening diagnostic hardware
Imaging — Molecular / Nuclear	27	20	6	Vereos Digital PET/CT, BrightView SPECT systems
Total	18,510	7,909	—	—

Category In-Depth Review

Other / Accessories (5,722 distinct registrations)

Other / Accessories represents the largest segment of Philips' global regulatory footprint, with 5,722 distinct registrations. This high volume is driven by the company's patient monitoring and respiratory care businesses, which require thousands of individual listings for cables, sensors, tubing, cuffs, and replacement parts. Under international medical device regulations, accessories that support the primary capital equipment must be registered separately. This allows Philips to legally import consumables and perform field upgrades without customs delays. Managing this vast catalog requires highly integrated Quality Management Systems (QMS) to ensure that replacement parts match the design files cleared in premarket notifications. For example, a patient monitor in an ICU requires different sensor attachments for pulse oximetry (SpO2), electrocardiography (ECG), non-invasive blood pressure (NIBP), and temperature monitoring. Each sensor must be registered under national databases to support hospital logistics. Any engineering update or change in materials must go through strict change control procedures to determine if new submissions are required, making this high-volume catalog a significant compliance management task. Furthermore, Philips must maintain compliance with material safety regulations, such as RoHS (Restriction of Hazardous Substances) and REACH in Europe. This requires checking raw material certificates from external suppliers, ensuring that patient-contacting sensors contain no restricted chemicals, satisfying the documentation audits of notified bodies.

Imaging — Ultrasound (449 distinct registrations)

Philips' ultrasound portfolio, centered on the Epiq and Affiniti series, holds 449 distinct registrations active across 18 markets. Diagnostic ultrasound is a core product line for Philips, challenging traditional market leaders. Premarket clearance for ultrasound systems focuses on proving the safety of patient-contacting materials under the ISO 10993 biocompatibility standards. Submissions must also document compliance with acoustic output limits established by international standards, including IEC 60601-2-37. Ultrasound systems utilize matrix transducer arrays and advanced software processing to generate real-time 3D images. Biocompatibility testing is critical for transesophageal (TEE) and intraoperative probes, which place transducers in direct contact with internal tissues. Philips' dossiers must include comprehensive cytotoxicity, sensitization, and irritation testing reports to secure clearances from health authorities. Additionally, Philips' ultrasound systems integrate AI algorithms to automate measurements in echocardiography. Submissions for these software modules must document software lifecycle controls in accordance with the IEC 62304 standard, demonstrating robust clinical validation.

Imaging — X-ray / Angiography (365 distinct registrations)

Philips' Azurion angiography suites and mobile C-arm systems hold 365 distinct registrations active across 17 markets. These systems are used to guide minimally invasive interventional cardiology and radiology procedures, requiring high-resolution, real-time imaging. Angiography suites must comply with safety requirements defined in the IEC 60601-2-43 standard. Premarket submissions must include detailed data on radiation dose optimization, ensuring patient safety during complex clinical procedures. Angiography suites involve complex system integration, coordinating table movements, C-arm rotation, and display monitors. Philips must perform extensive verification testing, including validating collision avoidance systems, to satisfy regulators. The technical files must document this system-level validation, requiring close cooperation between hardware and software engineering teams. These systems also feature advanced real-time image processing software. Philips' dossiers must prove that software latency is minimized to prevent display delays during critical catheterization procedures, maintaining mechanical safety.

Interventional / Advanced Therapies (361 distinct registrations)

This high-value category includes laser atherectomy catheters, specialized guidewires, and mapping systems. With 361 distinct registrations across nine markets, this portfolio represents a key commercial growth driver for Philips. These invasive devices are subject to strict premarket reviews, requiring clinical trial data demonstrating safety and efficacy in target populations. Manufacturing compliance is centered in specialized facilities, subject to regular audits by health authorities. Catheter-based therapies must show mechanical integrity and biocompatibility under ISO 10993. Clinical dossiers must document safety endpoints, such as low rates of vessel perforation and target lesion revascularization, to support marketing authorizations. The regulatory challenge in this segment centers on sterilizer validation, particularly for single-use catheters that utilize Ethylene Oxide (EtO) sterilization. Philips must document sterilization residuals in its regulatory dossiers, satisfying safety limits set by international standards (ISO 11135).

Digital Health / Software / IT (357 distinct registrations)

This category covers Philips' IntelliSpace PACS and clinical software suites. As software-as-a-medical-device (SaMD) regulations evolve, Philips must maintain detailed software lifecycle documentation, cybersecurity risk assessments, and clinical evaluation dossiers in accordance with the IEC 62304 standard to secure approvals. Software development must follow strict verification and validation protocols, documenting bug tracking, software architecture, and risk analysis. As cloud-based monitoring portals expand, cybersecurity compliance has become a key regulator focus, requiring Philips to submit penetration testing results and encryption descriptions. Additionally, Philips' software must comply with interoperability standards (such as DICOM and HL7), allowing for seamless integration with electronic health records (EHR) in hospitals. Submissions must document conformance testing, satisfying technical audits from healthcare IT buyers.

Imaging — MRI (281 distinct registrations)

Philips' Ingenia and Elition MRI series hold 281 distinct registrations across 15 markets. The premarket clearance process for MRI scanners focuses on magnetic field safety, time-varying gradient magnetic fields, and radiofrequency (RF) tissue heating (Specific Absorption Rate - SAR limits) under the IEC 60601-2-33 standard. MRI systems utilize liquid helium to cool the superconducting magnet, requiring specialized installation and cryogenic safety controls. Philips' dossiers must document quench venting safety, RF shielding, and acoustic noise reduction systems to secure marketing clearances. Additionally, Philips' MRI systems feature helium-free operations (such as the BlueSeal magnet), which utilize a sealed cooling system containing only a micro-fraction of liquid helium. Registrations for these systems must highlight this technology, explaining how it mitigates cryogenic risks during emergency quenches.

Imaging — CT (229 distinct registrations)

The Incisive and Spectral CT series hold 229 distinct registrations active across 18 markets. Premarket submissions focus on radiation dose reduction technologies and image reconstruction speed under the IEC 60601-2-44 standard. Philips CT scanners integrate spectral imaging capabilities, allowing for tissue characterization and improved contrast. Premarket submissions must include phantom imaging results and dose measurements (CTDIvol) to prove compliance with dose limits. The premarket reviews for CT systems also evaluate mechanical safety, including gantry rotation stability and patient table load capacity. Submissions must document engineering test reports showing compliance with standard safety limits.

Imaging — General / Other (187 distinct registrations)

This category covers digital radiography rooms and detectors. Philips holds 187 distinct registrations across five markets, focusing on municipal hospital tenders. General radiography platforms must comply with regional radiation safety standards, including FDA's ionizing radiation performance standards under 21 CFR Subchapter J.

Radiation Oncology (82 distinct registrations)

Philips' Pinnacle treatment planning software holds 82 distinct registrations active across 22 markets. This software is subject to strict premarket reviews, requiring software lifecycle documentation under the IEC 62304 standard. Pinnacle calculations determine therapeutic radiation doses for cancer patients. Software bugs can lead to incorrect exposure, making clinical validation and software hazard analysis critical components of the regulatory file.

Laboratory Diagnostics (53 distinct registrations)

Unlike Siemens Healthineers, Philips maintains a very small footprint in Laboratory Diagnostics, with 53 registrations. The company has focused its resources on active medical equipment and software rather than automated clinical chemistry reagents.

Hearing / Audiology (24 distinct registrations)

This category covers infant hearing screening diagnostic hardware. Registrations are active in four markets, representing a minor segment of Philips' overall compliance portfolio.

Imaging — Molecular / Nuclear (20 distinct registrations)

Vereos Digital PET/CT and BrightView SPECT systems hold 20 registrations active across 16 markets, requiring compliance with both radiological safety standards and radioactive material regulations.

Non-Registration Evidence Layers: Patents and Clinical Trials

To validate Philips' commercial and scientific footprint, we analyzed non-registration data layers, focusing on active clinical trials, patent filings, and federal procurement.

Clinical Trials Activity (ClinicalTrials.gov)

A search of the ClinicalTrials.gov database identifies 22 studies that name Philips directly in the study title, drawn from a broader set of 205 Philips-sponsored studies. Key clinical trials include:

NCT02529137 (Pivotal Study for Validation of Philips Dx): A clinical trial evaluating the diagnostic performance and accuracy of Philips' diagnostic software tools.
NCT06682312 (Non-Invasive Blood Pressure Study): A study validating next-generation patient monitoring algorithms and sensors in clinical environments.
AI-Guided Diagnostics: Multiple active trials testing the clinical workflow improvements of Philips' IntelliSpace PACS and AI-assisted imaging tools.

Patent and Intellectual Property Analysis (USPTO)

A search of the US Patent and Trademark Office (USPTO) database reveals 681 active patents relating to ultrasound technology assigned directly to Philips. This large patent portfolio demonstrates a continuous investment in diagnostic imaging IP:

Transducer Innovation: Patents covering advanced 2D and 3D matrix transducer arrays used in transesophageal echocardiography (TEE) and general abdominal imaging.
Beamforming Algorithms: IP protecting digital beamforming methods that improve contrast resolution and image quality in real-time.
AI-Assisted Image Analysis: Patents detail machine-learning algorithms that automate cardiac measurements and lesion detection.

US Federal Government Procurement (USAspending)

A match against the USAspending database identifies 166 federal procurement contracts awarded to Philips entities. These contracts are dominated by:

Defense Logistics Agency (DLA): High-value capital equipment contracts supporting the US military healthcare system (TRICARE).
Department of Veterans Affairs (VA): Multi-year service and acquisition contracts for Philips' Ingenia MRI and Azurion angiography systems installed in VA hospitals nationwide.

Data Limitations & Compliance Boundaries

When using this global regulatory intelligence dossier, compliance managers must consider several structural data limitations:

Product-Level vs. Dealer-Level Coverage: In countries like Singapore and Malaysia, the registration reflects the product-level approval tied to the manufacturer. However, in other countries (such as parts of the MEA region), registrations may be tied to the local distributor's license. Consequently, a single product line may appear as multiple records in the database if it is imported by different local dealers.
EUDAMED Transition Status: The EU EUDAMED database count represents certified products under the new MDR/IVDR framework. It does not include all active legacy devices currently sold under transitional provisions, meaning the actual commercial footprint in Europe is larger than the registry-level footprint.
Absence of Data: For markets like Moldova (0 registrations) and Egypt (0 registrations), the database count is zero. This reflects a registry framework that focuses on licensing the importer or local establishment, rather than maintaining a public database of individual device listings.
Trade-Market Context vs. Company Sales: International trade datasets (HS code customs records) are generally compiled at the product category level (e.g., "9018.12 - Ultrasonic Scanning Apparatus") and do not always identify the manufacturer. In this dossier, trade data is utilized for regional market context only and is not counted toward Philips' company-specific sales or registration figures.

Decision-Making Framework for Global Market Entry

To assist regulatory affairs directors and business development teams, we have outlined a decision-making framework for selecting target markets based on competitor density:

                            +---------------------------------------+
                            |       Identify Target Modality        |
                            |      (e.g., Ultrasound, Imaging)      |
                            +-------------------+-------------------+
                                                |
                                                v
                            +---------------------------------------+
                            |     Cross-Reference Matrix Density    |
                            |     - High Density: Philips present   |
                            |     - Low Density: Philips absent     |
                            +-------------------+-------------------+
                                                |
                        +-----------------------+-----------------------+
                        |                                               |
                        v                                               v
          +---------------------------+                   +---------------------------+
          |       High Density        |                   |        Low Density        |
          |    (Mature Competitor)    |                   |       (Whitespace)        |
          +-------------+-------------+                   +-------------+-------------+
                        |                                               |
                        v                                               v
          +---------------------------+                   +---------------------------+
          | Benchmark Philips' Local  |                   | Evaluate Entry Barriers:  |
          | Distributor Agreements or |                   | - Local agent requirement |
          | Subsidiary Presence       |                   | - Testing/Clinical needs  |
          +-------------+-------------+                   +-------------+-------------+
                        |                                               |
                        v                                               v
          +---------------------------+                   +---------------------------+
          | Formulate Differentiated  |                   | Secure First-Mover Status |
          | Regulatory Pathway (e.g., |                   | via Fast-Track reliance   |
          | Special vs. Traditional)  |                   | (e.g., FDA/CE approval)   |
          +---------------------------+                   +---------------------------+

Strategic Action Items

Identify Whitespace Opportunities: Cross-reference the consolidated registration matrix to find markets where Philips is absent but other competitors are active. For example, in Colombia, Philips has zero registrations under the "Interventional / Advanced Therapies" category, whereas other competitors hold a combined 19 registrations. This indicates a clear entry point for interventional cardiology devices.
Leverage Regulatory Reliance: In countries with high registration counts for Philips (such as Australia and Taiwan), new entrants should utilize regulatory reliance pathways. Submitting files that highlight existing US FDA 510(k) clearances or EU CE certifications can significantly reduce the local review timeline.
Monitor Distributor Concentration: In emerging markets, Philips relies on local agents. RA teams must monitor national databases for updates to local representative licenses, ensuring that local partners have the capacity to maintain compliance.

Competitor Density Reading

The country table doubles as a competitor-density map. Philips' EU concentration (2,877 distinct registrations) reflects the heavy MDR/IVDR transition load the company carries in Europe, and the US figure (1,403) is shaped in part by the Respironics consent decree, which narrowed the active respiratory portfolio. The mid-tier APAC hubs (Australia 588, Taiwan 488, Singapore 374) are markets where Philips has already absorbed the cost of local Sponsor/representative setup and language translation, making them competitive strongholds. By contrast, the single-digit markets (Japan 6, Ukraine 7, Jordan 1, Kenya 1, South Africa 1) indicate thin product-level presence, typically managed through establishment-level licensing or dealer-based import notifications. An entrant weighing market selection should treat the high-density EU, US, and APAC hubs as differentiation contests (where service, price, or clinical evidence must beat an entrenched incumbent) and the low-density markets as first-mover opportunities reachable through regulatory reliance on FDA or CE clearances.

Frequently Asked Questions (FAQs)

How many distinct medical device registrations does Philips hold in the European Union compared to the US?

Philips holds 2,877 distinct registrations in the European Union (EUDAMED database) compared to 1,403 distinct registrations in the United States (FDA database). This indicates that Europe is Philips' primary regulatory focus, containing more than double its US registration volume.

What are the top three business categories for Philips in terms of global registration volume?

The top three business categories for Philips are Other / Accessories (5,722 registrations), Imaging — Ultrasound (449 registrations), and Imaging — X-Ray / Angiography (365 registrations). These categories represent the core of Philips' active product lines.

Why does the "Other / Accessories" category represent such a large portion of Philips' portfolio?

This category covers clinical consumables, sensors, cables, and replacement parts that support Philips' massive installed base of patient monitoring systems and diagnostic imaging hardware. Each unique component must be registered separately, resulting in a large number of individual database listings.

What regulatory certification is required for Philips to export to Taiwan?

To export medical devices to Taiwan, Philips must secure a Quality System Documentation (QSD) approval from the Taiwan Food and Drug Administration (TFDA). This approval certifies that the manufacturing facility complies with Taiwan's medical device Good Manufacturing Practices (GMP) or ISO 13485 standard.

What role does the Medical Device Single Audit Program (MDSAP) play in Philips' global registrations?

Philips utilizes MDSAP audit certificates to satisfy quality system requirements in multiple participating jurisdictions, including the US FDA, Health Canada, Brazil's ANVISA, and Australia's TGA. This program allows a single audit to cover compliance for multiple international markets, significantly reducing audit overhead.

What is the significance of the Azurion in Philips' angiography portfolio?

The Azurion is Philips' flagship angiography and interventional radiology platform. Securing global approvals for this platform required demonstrating compliance with the IEC 60601-2-43 standard and submitting data on radiation dose optimization, ensuring patient safety during complex clinical procedures.

How are Philips' software applications regulated globally?

Philips' clinical software (such as the IntelliSpace PACS) is regulated as Software as a Medical Device (SaMD). In mature markets, Philips must maintain detailed software lifecycle documentation, cybersecurity risk assessments, and clinical evaluation dossiers in accordance with the IEC 62304 standard to secure approvals.

How many clinical trials does Philips hold in ClinicalTrials.gov?

A search of the ClinicalTrials.gov database identifies 205 Philips-sponsored studies, of which 22 name Philips directly in the study title. These trials cover diagnostic performance, sensor accuracy, and workflow optimization.

How many ultrasound patents does Philips hold in the USPTO?

The FDA consent decree regarding Philips' Respironics division has required the company to implement comprehensive QMS remediation plans and coordinate closely with the FDA to manage recall distribution and patient monitoring updates. This safety action has significantly impacted Philips' regulatory focus in the US.

What post-market vigilance reports must Philips file in the EU?

In the European Union, Philips must comply with the MDR's post-market surveillance (PMS) requirements, which include compiling Periodic Safety Update Reports (PSURs) for Class IIa, IIb, and III devices. These reports must summarize safety data, recall actions, and clinical findings, and must be submitted to Notified Bodies.

What are the translation requirements for medical device registration in Saudi Arabia?

Under Saudi Food and Drug Authority (SFDA) regulations, all medical device labeling, instructions for use (IFUs), and safety manuals must be available in both English and Arabic. Philips maintains dedicated translation management systems to ensure compliance for MDMA approvals.

How does Philips manage compliance changes in CDSCO regulations in India?

India's CDSCO has transitioned to a comprehensive licensing framework under the Medical Devices Rules 2017. Philips manages this transition through its local regulatory division in Gurgaon, updating quality systems and submitting import license applications for its entire product range in compliance with national deadlines.

Why does Philips have a small footprint in Laboratory Diagnostics compared to Siemens?

Philips has strategically focused its resources on active medical equipment and clinical software rather than automated clinical chemistry reagents. This focus is reflected in its global registration matrix, which contains only 53 listings for Laboratory Diagnostics compared to Siemens' 9,050 listings.

What is the significance of the Pinnacle software in Philips' oncology portfolio?

The Pinnacle treatment planning software is a core oncology product, holding 82 distinct registrations active across 22 markets. Because it calculates therapeutic radiation doses, it is classified as high-risk medical software, requiring strict compliance with the IEC 62304 standard.

How are Philips' MRI systems evaluated for safety?

Philips' MRI systems are evaluated under the IEC 60601-2-33 standard, which governs safety requirements for magnetic resonance diagnostic equipment. Testing covers static magnetic fields, gradient magnetic fields, radiofrequency tissue heating, acoustic noise limits, and cryogenic helium venting systems.

What is the regulatory process for Philips in Brazil's ANVISA?

To register Class III or IV systems in Brazil, Philips must secure Brazilian Good Manufacturing Practices (BGMP) certification from ANVISA. This certification involves auditing manufacturing plants, though ANVISA increasingly accepts MDSAP audit certificates to accelerate reviews.

What are the regulatory standards for Philips' ultrasound systems?

Philips' ultrasound platforms must comply with IEC 60601-2-37 safety standards, which govern acoustic output limits. In addition, transducer arrays must undergo biocompatibility testing under the ISO 10993 series to verify patient-contacting material safety.

How does Health Canada regulate Philips' software upgrades?

Significant software modifications to Class III or IV systems require Philips to submit a Medical Device License Amendment (MDLA) to Health Canada. Submissions must document software verification, risk hazard assessments, and clinical evaluation files to secure clearance.

What is the role of a UK Responsible Person (UKRP) for Philips?

Following Brexit, foreign manufacturers exporting to the UK must appoint a UKRP to register devices with the MHRA. The UKRP acts as the primary liaison for vigilance reporting, maintains technical documentation, and verifies that products meet UKCA requirements.

What are the specific safety actions required for Philips' CPAP recall?

The CPAP safety action required Philips to replace the PE-PUR sound abatement foam in millions of devices globally. This process was audited by the FDA and other international health authorities, requiring detailed tracking of returned units, shipping logs, and replacement material biocompatibility validations.

What is the role of the EUDAMED database in Europe?

EUDAMED is the European Database on Medical Devices, designed to improve transparency and coordination. It consists of six modules, covering actor registration, UDI and device registration, certificates, clinical investigations, vigilance, and market surveillance. Philips maintains thousands of active listings in this centralized system.

How does Philips manage compliance for its BlueSeal helium-free MRI systems?

Philips' BlueSeal MRI systems utilize a fully sealed cooling system containing a micro-fraction of the liquid helium used in traditional scanners. To register these systems, Philips must present technical data demonstrating that the sealed magnet eliminates the risk of helium venting during a quench, reducing installation compliance hurdles.

What are the regulatory standards for sterile catheters?

Invasive catheters must comply with ISO 11135 standards for Ethylene Oxide (EtO) sterilization validation. Submissions must document sterilization cycle parameters, biological indicator audits, and gas residue levels to ensure patient safety and verify compliance.

How are Philips' patient monitors evaluated for electromagnetic compatibility?

Philips' patient monitors must comply with the IEC 60601-1-2 standard for electromagnetic compatibility (EMC). This testing ensures that monitors can operate safely in high-EMI clinical environments (such as operating rooms and ICU suites) without interfering with or being affected by other active medical equipment.

What post-market clinical follow-up (PMCF) requirements apply to Philips in the EU?

Under the EU MDR, Philips must implement PMCF activities to continuously collect and evaluate clinical data for its CE-marked devices. This includes conducting post-market clinical trials, compiling patient registries, and analyzing user feedback to verify that long-term safety and performance profiles are maintained.

How does the MHRA regulate Philips' products post-Brexit?

Following Brexit, the MHRA acts as the sole regulator for medical devices in Great Britain. Philips must register all devices sold in the UK market under the UKCA framework. This requires appointing a UK Responsible Person (UKRP) and submitting CE certificates or UKCA conformity assessments.

What is the process for registering Philips' products in Colombia's INVIMA?

To register devices in Colombia, Philips must secure a Sanitary Registry (Registro Sanitario) from INVIMA. The process requires submitting a technical dossier containing ISO 13485 quality certificates, INMETRO or other international testing reports, and clinical evaluation files in Spanish.

What are the electrical safety standards for Philips' C-arms?

Philips' mobile C-arm angiography systems must comply with the IEC 60601-1 general standard for electrical safety and the IEC 60601-2-43 particular standard for X-ray equipment used in interventional procedures, ensuring protection against electrical shock and stray radiation.

How does Philips manage software cybersecurity in its patient monitoring systems?

Philips manages cybersecurity by implementing secure software lifecycles (IEC 62304), incorporating data encryption, secure authentication, and regular vulnerability scanning. Submissions to the FDA and EU Notified Bodies must include comprehensive threat models and software bill of materials (SBOM).

What is the significance of the BlueSeal magnet in MRI market access?

The BlueSeal magnet is a key competitive differentiator that eliminates the helium-refilling requirement. From a regulatory standpoint, it reduces cryogenic safety hazards (helium venting), simplifies hospital installation approvals, and bypasses local environmental venting permits.

How does Philips coordinate registrations in the ASEAN region?

Philips coordinates registrations by compiling a Common Submission Dossier Template (CSDT) aligned with the ASEAN Medical Device Directive (AMDD). This standardized technical file is adapted for national health authorities in Singapore, Malaysia, Indonesia, and Thailand, reducing duplication.

A local Sponsor acts as the legal representative for Philips in Australia. The Sponsor must be a resident of Australia or an Australian-incorporated entity. They hold the TGA registration, manage vigilance reporting, and coordinate with the TGA during safety actions.

What is the difference between Class IIa and Class IIb software in the EU MDR?

Under EU MDR Rule 11, software intended for diagnostic decisions is classified as Class IIa unless it can cause death or irreversible deterioration, in which case it is Class IIb or Class III. Most of Philips' clinical software is Class IIa or IIb, requiring direct Notified Body audit.

How does Philips validate materials for chemical compliance under REACH?

Philips validates materials by conducting supply chain audits and collecting declarations of conformity from component suppliers. Reagents, sensors, and structural plastics are tested for Substance of Very High Concern (SVHC) levels to satisfy EU REACH requirements.

What is the process for registering devices in South Korea's MFDS?

To register medical devices in South Korea, Philips must submit technical files to the Ministry of Food and Drug Safety (MFDS). Submissions must include clinical data, quality system certificates (KGMP), and test reports verifying safety and efficacy under Korean national standards.

How does Argentina's ANMAT regulate imported medical devices?

Argentina's ANMAT regulates imported devices by requiring a local Authorized Representative to hold the sanitary registry. Importers must demonstrate compliance with Good Manufacturing Practices (GMP) and maintain authorized storage facilities audited by ANMAT.

What are the regulatory challenges of Philips' Vereos Digital PET/CT?

The Vereos Digital PET/CT is a hybrid imaging system requiring compliance with both radiological safety standards and nuclear regulatory guidelines. Submissions must document dose management, system integration, and radiation shielding designs to secure clearances.

Under the FDA consent decree, Philips must maintain a Recall Coordination Center to manage international corrective actions. This involves tracking affected units by serial number, coordinating replacement parts, and submitting progress reports to health authorities.

What are the translation requirements for medical device registrations in the EU?

Under the EU MDR, all device labeling, instructions for use (IFUs), and safety manuals must be translated into the official languages of the EU Member States where the product is marketed, ensuring safety for clinical users and patients.

How does the EAEU regulatory harmonization affect registrations in Kazakhstan?

The Eurasian Economic Union (EAEU) harmonization aims to create a unified medical device registry across member states (including Kazakhstan and Russia). Manufacturers must transition from national registrations to EAEU-compliant technical files.

What is the significance of the Pinnacle treatment planning software?

Pinnacle is a core oncology product holding 82 distinct registrations. Because it calculates radiation therapy doses, it is classified as Class IIb (EU) or Class II (US) medical software, requiring strict software lifecycle documentation (IEC 62304) and risk hazard analysis (ISO 14971).

How does Philips manage environmental compliance for its packaging materials globally?

Philips manages environmental compliance by designing packaging that complies with global directives (such as the EU Packaging and Packaging Waste Directive). Packaging materials must be recyclable, minimize toxic substances, and comply with national waste recovery systems (such as the Green Dot system in Europe).

What are the clinical data requirements for Philips' Azurion in China?

To register the Azurion angiography platform with China's NMPA, Philips must present comprehensive clinical trial data demonstrating safety and efficacy in Chinese patients. This often involves conducting local clinical trials or participating in global multi-center trials with Chinese patient cohorts.

What is the process for registering devices in Mexico's COFEPRIS?

To register medical devices in Mexico, Philips must submit technical files to COFEPRIS. Submissions require quality system certificates, testing reports, and clinical evaluation files in Spanish. Mexico offers expedited review pathways for devices that already hold US FDA clearance or Health Canada approval.

What is the significance of the Incisive CT scanner?

The Incisive CT scanner is a core diagnostic product designed to minimize operational costs and improve throughput. Registrations focus on validating dose reduction technologies (DoseWise Portal) and mechanical safety, meeting international standards.

How does Philips manage compliance for its pediatric patient monitoring lines?

Philips validates pediatric monitors by conducting specialized clinical evaluations to verify sensor accuracy on infants and pediatric patients. technical files must document safety profiles, alarm management systems, and specialized sensor designs to satisfy regulators.

What is the difference between "matched records" and "distinct registrations" in this analysis?

A matched record is any row in the consolidated registry matrix that maps to Philips; a distinct registration is a unique registration key (marketing authorization) after de-duplication. Philips shows 18,510 matched records but 7,909 distinct registrations because the same product recurs across registries, status states, and distributor entries. The distinct count is the truer measure of Philips' compliant product portfolio.

Why is the EU Philips' largest registry concentration rather than the US?

The EU total (2,877 distinct registrations) reflects the heavy MDR/IVDR transition load—Philips must actively re-certify legacy devices to keep them on the European market. The US figure (1,403) is comparatively smaller and has also been shaped by the Respironics consent decree, which narrowed the active respiratory portfolio. The result is that Europe, not the US, carries the largest share of Philips' current registered assets in this dataset.

How does Philips manage accessories change-control across its 5,722 accessory registrations?

Philips' accessory volume is driven by patient-monitoring and respiratory consumables—cables, sensors, tubing, and cuffs—each registered separately in every market. A material or supplier change triggers an engineering change order evaluation to decide whether a registration amendment is required. Given the scale, Philips uses a change-control matrix that maps every modification to affected jurisdictions, preventing silent lapses in any single market.

What is the role of the IntelliSpace PACS in Philips' software registrations?

The IntelliSpace PACS and related clinical software suites are regulated as Software as a Medical Device (SaMD), classified mostly as Class IIa or IIb under the EU MDR. Philips maintains software lifecycle documentation under IEC 62304, cybersecurity risk assessments, and interoperability conformance testing (DICOM, HL7) so the platforms integrate with hospital electronic health records across the 18 markets where they are registered.

How does Philips coordinate ASEAN registrations through Singapore?

Singapore serves as Philips' regional hub for ASEAN filings. By maintaining a Common Submission Dossier Template (CSDT) master file, Philips adapts one technical dossier for Singapore (374 registrations), Malaysia (202), Indonesia (311), and Thailand (47), reducing duplicated translation and testing work while satisfying each national authority's specific labeling and distributor requirements.

This global regulatory intelligence dossier is based on consolidate registry exports and federal procurement data current as of June 26, 2026. Analysis compiled by MedDeviceGuide.